Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy-Reference-Cited by-同舟云学术

Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy

Published:2014-08 Issue: Volume:108 Page:94-103
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

Diotti Roberta Antonia,Mancini Nicasio,Clementi Nicola,Sautto Giuseppe,Moreno Guisella Janett,Criscuolo Elena^ORCID,Cappelletti Francesca^ORCID,Man Petr,Forest Eric,Remy Louise,Giannecchini Simone^ORCID,Clementi Massimo,Burioni Roberto

Publisher

Elsevier BV

Subject

Virology,Pharmacology

Reference71 articles.

1. Progressive multifocal leukoencephalopathy;Aksamit;Continuum (Minneap Minn),2012

2. Antibody against synthetic multiple antigen peptides (MAP) of JC virus capsid protein (VP1) without cross reaction to BK virus: a diagnostic tool for progressive multifocal leukoencephalopathy;Aoki;Neurosci. Lett.,1996

3. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin’s disease;Astrom;Brain,1958

4. A combination of low-dose chlorpromazine and neutralizing antibodies inhibits the spread of JC virus (JCV) in a tissue culture model: implications for prophylactic and therapeutic treatment of progressive multifocal leukoencephalopathy;Atwood;J. Neurovirol.,2001

5. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies;Bellizzi;J. Neurovirol.,2012

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JCPyV VP1 Mutations in Progressive Multifocal Leukoencephalopathy: Altering Tropism or Mediating Immune Evasion?;Viruses;2020-10-12

2. Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines;Journal of Immunology Research;2019-03-04

3. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis;Multiple Sclerosis and Related Disorders;2018-02

4. Infectious Entry and Neutralization of Pathogenic JC Polyomaviruses;SSRN Electronic Journal;2018

5. Prevention and therapy of JC polyomavirus-mediated progressive multifocal leukoencephalopathy – a realistic possibility?;Swiss Medical Weekly;2017-10-31